why choose us

First received: August 5, 2022

Clinical Trial: Named Patient Program for Mitomycin for Pyelocalyceal Solution

Condition: Urothelial Cancer of Renal Pelvis
Urothelial Carcinoma of the Renal Pelvis and Ureter
Urot

Study Type: Expanded Access


Official Title: Not Provided

Brief Summary: This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

Read more